Doxofylline

Doxofylline is an orally active PDE IV inhibitor and A1AR antagonist. Doxofylline reduces inflammation in epithelial cells via inhibiting mitochondrial ROS production and amelioration of multiple cellular pathways (NLRP3-TXNIP inflammasome activation) . Doxophylline can be used in studies of asthma, chronic obstructive pulmonary disease, and bronchospasm[1][2][3].

Product Specifications

CAS Number

[69975-86-6]

UNSPSC

12352005

Hazard Statement

H302

Target

Adenosine Receptor; Phosphodiesterase (PDE) ; Reactive Oxygen Species (ROS)

Type

Reference compound

Related Pathways

GPCR/G Protein; Immunology/Inflammation; Metabolic Enzyme/Protease; NF-κB

Applications

COVID-19-immunoregulation

Field of Research

Inflammation/Immunology

Assay Protocol

https://www.medchemexpress.com/Doxofylline.html

Purity

99.97

Solubility

DMSO : 50 mg/mL (ultrasonic) |H2O : 25 mg/mL (ultrasonic)

Smiles

O=C(N1C)N(C)C2=C(N(CC3OCCO3)C=N2)C1=O

Molecular Formula

C11H14N4O4

Molecular Weight

266.25

Precautions

H302

References & Citations

[1]Jiao P, et al. The protective effect of doxofylline against lipopolysaccharides (LPS) -induced activation of NLRP3 inflammasome is mediated by SIRT1 in human pulmonary bronchial epithelial cells. Artif Cells Nanomed Biotechnol. 2020 Dec;48 (1) :687-694. |[2]Riffo-Vasquez Y, et al. Doxofylline, a novofylline inhibits lung inflammation induced by lipopolysacharide in the mouse. Pulm Pharmacol Ther. 2014 Apr;27 (2) :170-8.|[3]Shukla D, et al. Doxofylline: a promising methylxanthine derivative for the treatment of asthma and chronic obstructive pulmonary disease. Expert Opin Pharmacother. 2009 Oct;10 (14) :2343-56.